UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 13, 2021

NextCure, Inc.

(Exact name of registrant as specified in charter)

Delaware

(State or other jurisdiction of incorporation)

001-38905 (Commission File Number) 47-5231247

20705

(Zip Code)

(IRS Employer Identification No.)

9000 Virginia Manor Road, Suite 200

Beltsville, Maryland

(Address of principal executive offices)

(240) 399-4900

Registrant's telephone number, including area code

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

D Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.001 par value per share	NXTC	Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company \boxtimes

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 7.01 Regulation FD Disclosure

On November 13, 2021, NextCure, Inc. (the "Company") issued a press release announcing new data from two clinical studies and one research study presented at the Society for Immunotherapy of Cancer (SITC) annual meeting in Washington, D.C., and on a virtual platform. The data come from clinical studies evaluating NC318, a Siglec-15 (S15) antibody, and NC410, a fusion protein of LAIR-2, in patients with advanced/metastatic solid tumors, as well as from a research study evaluating NC410's impact on T cell activation and myeloid cell polarization conducted in collaboration with the National Cancer Institute at the National Institutes of Health. The Company is furnishing a copy of the press release, which is attached hereto as Exhibit 99.1.

On November 15, 2021, the Company is hosting a Virtual Oncology Pipeline Update Event. The presentation for such virtual event is being furnished as Exhibit 99.2 hereto. A live webcast of the event will be available through the Investors section of the Company's website at www.nextcure.com. A replay of the webcast will be available approximately two hours after the event and archived on the website for 30 days. The Company's website and any information contained on the website are not incorporated into this Current Report on Form 8-K.

The information furnished in this Item 7.01 (including Exhibit 99.1 and Exhibit 99.2) shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and is not incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits.

Exhibit

Number	Description
<u>99.1</u>	Press release issued by NextCure, Inc. dated November 13, 2021
<u>99.2</u>	Investor presentation issued by NextCure, Inc. dated November 15, 2021
104	Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 15, 2021

NEXTCURE, INC.

/s/ Steven P. Cobourn Steven P. Cobourn Chief Financial Officer



NextCure and Collaborators Provide Clinical and Research Updates on NC318 and NC410 Candidates at Society for Immunotherapy of Cancer Annual Meeting

BELTSVILLE, Md. – November 13, 2021 -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced new data from two clinical studies and one research study presented at the Society for Immunotherapy of Cancer (SITC) annual meeting in Washington, D.C., and on a virtual platform. The data come from clinical studies evaluating NC318, a Siglec-15 (S15) antibody, and NC410, a fusion protein of LAIR-2, in patients with advanced/metastatic solid tumors, as well as from a research study evaluating NC410's impact on T cell activation and myeloid cell polarization conducted in collaboration with the National Cancer Institute at the National Institutes of Health.

"We are pleased to share promising data from our NC318 and NC410 programs at this year's SITC annual meeting," said Han Myint, MD, NextCure's chief medical officer. "Results from our ongoing Phase 1 and Phase 2 trials suggest that NC318 may have a clinical benefit in patients. Retrospective analysis of patient biopsies from the Phase 1 and Phase 2 trials showed better outcomes in S15+ patients compared to S15- patients receiving NC318. Selecting for patients with S15+ expression coupled with a higher and more frequent dosing regimen that increases overall drug exposure is anticipated to impact clinical outcomes. Additionally, data from our NC410 program show that NC410 is safe and well-tolerated

in patients and demonstrates early indications of immune modulation. We look forward to continuing the advancement of both programs to improve the treatment landscape for cancer patients."

Details of the oral and poster presentations are below:

Clinical benefit through S15 targeting with NC318 antibody in subjects with S15 positive advanced solid tumors

Combined Phase 1 and Phase 2 data from the NC318 study show early evidence of possible clinical benefit in patients with lung cancer, squamous cell carcinoma of the head and neck and breast cancer and other advanced/metastatic solid tumors with dosing once every two weeks during dose escalation and with the 400mg dose selected for the Phase 2 studies. Highlights include:

- Data are derived from patient cohorts in both Phase 1 (n=49) and Phase 2 (n=47) of these studies.
- One NSCLC CR and one NSCLC PR patient from the Phase 1 study remain on therapy for 2.8 and 2.2 years, respectively.
- NC318 appears to show evidence of disease control with better outcomes in S15+ patients compared to S15- patients.
- The disease control rate across all tumors in both studies was 37% with a median progression-free survival (PFS) of 5.0 months.
- Patients in the lung cohort from both studies showed 45% disease control rate with a median PFS of 5.2 months.

Data indicate that soluble S15 (sS15) level may serve as a biomarker for patient selection.
 Pharmacokinetic and pharmacodynamic modeling predict that a dose of 800 mg once a week results in nearly 10 times greater drug exposure which may impact drug activity and clinical outcomes.

NC410, a fusion protein of LAIR-2 (Leukocyte Associated Immunoglobulin-like Receptor) fused to human IgG1 Fc domain appears safe and well-tolerated with evidence of immune modulation in subjects with advanced solid tumors

Interim data presented from the Phase 1 dose-escalation study show that NC410 appears to be safe and well-tolerated in patients with advanced tumors and show evidence of immune modulation. Highlights include:

- The data come from the first five patient cohorts (n=19), who received doses of NC410 up to 60 mg once every two weeks.
- There were no dose-limiting toxicities.
- Data show a transient reduction in peripheral C1q, suggesting target binding of NC410.
- LAIR-2 levels in peripheral blood increase in a dose-dependent fashion and may suggest mechanistic evidence of immune normalization.
 Early evidence of extracellular matrix (ECM) remodeling and immune activation was shown by an increase in serum C4G, a Granzyme B-mediated collagen fragment, and a reduction in serum Pro-C3 and Pro-C6 fragments.
- Time-dependent increase in CD4+ and CD8+ T cells without an increase in LAIR-1 expression provides further early evidence of immune activation.
- Safety, tolerability, efficacy, and biomarker analyses are ongoing in higher dose cohort patients.

Blockade of the inhibitory collagen receptor LAIR-1, PD-L1, and TGF-β promotes anti-tumor activity through T cell activation and myeloid cell polarization

Non-clinical data from a research study conducted in collaboration with the National Cancer Institute at the National Institutes of Health show NC410's impact on T cell activation, myeloid cell polarization and anti-tumor activity. Highlights include:

- NC410 and bintrafusp alpha, a TGF-beta trap molecule, synergize for effective tumor control in a mouse model of colon cancer.
- Tumor control is mediated by an increase in activated CD8+ T cells and a reduction in M2 tumor-associated macrophages in tumor infiltrates.
- Collagen remodeling is demonstrated in tumors treated with NC410.

About NC318

NC318 is a first-in-class immunomedicine against Siglec-15 (S15), a novel immunomodulatory target found on highly immunosuppressive cells called M2 macrophages in the tumor microenvironment and on certain tumor types including lung, ovarian and head and neck cancers. In preclinical research, it was observed that S15 promoted the survival and differentiation of suppressive myeloid cells and negatively regulated T cell function, allowing cancer to avoid immune destruction. In preclinical studies, NC318 blocked the negative effects of S15. NextCure believes NC318 has the potential to treat multiple cancer types.

About NC410

NC410 is a first-in-class immunomedicine designed to block immune suppression mediated by LAIR-1, an immunomodulatory receptor expressed on T cells and myeloid cells, including dendritic cells, a type of antigen presenting cell. In preclinical research, it has been shown that LAIR-1 inhibits T cell function and myeloid activity. In preclinical studies, NC410 blocks the negative effects of LAIR-1 and promotes T cell function and myeloid cell activity. NextCure believes NC410 has the potential to treat multiple cancer types.

About NextCure, Inc.

NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases. Through our proprietary FIND-IO[™] platform, we study various immune cells to discover and understand targets and structural components of immune cells and their functional impact in order to develop immunomedicines. Our initial focus is to bring hope and new treatments to patients who do not respond to current cancer therapies, patients whose cancer progresses despite treatment and patients with cancer types not adequately addressed by available therapies. http://www.nextcure.com

Cautionary Statement Regarding Forward-Looking Statements

Statements made in this press release that are not historical facts are forward-looking statements. Words such as "expects," "believes," "intends," "hope," "forward" and similar expressions are intended to identify forward-looking statements. Examples of forward-looking statements in this press release include, among others, statements about NextCure's plans, objectives, and intentions with respect to the discovery of immunomedicine targets and the discovery and development of immunomedicines. Forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those projected in any forward-looking statement. Such risks and uncertainties include, among others: our limited operating history and no products approved for commercial sale; our history of significant losses; our need to obtain additional financing; risks related to clinical development, including that early clinical data may not be confirmed by later clinical results; risks that pre-clinical research may not be confirmed in clinical trials; risks related to marketing approval and commercialization; and the unproven approach to the discovery and development of product candidates based on our FIND-IO platform. More detailed information on these and additional factors that could affect NextCure's actual results are described in NextCure's filings with the Securities and Exchange Commission (the "SEC"), including NextCure's most recent Form 10-K and subsequent Form 10-Q. You should not place undue reliance on any forward-looking statements. NextCure assumes no obligation to update any forward-looking statements, even if expectations change.

Investor Inquiries

Timothy Mayer, Ph.D. NextCure, Inc. Chief Operating Officer (240) 762-6486 <u>IR@nextcure.com</u>



Investor Update

November 15, 2021


Forward-Looking Statements

To the extent that statements contained in this presentation are not descriptions of historical facts, they may be deemed to be forwardlooking statements under the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "anticipate," "estimate," "intend," "next," "near-term," "future" and similar expressions, as well as other words and expressions referencing future events, conditions, or circumstances, are intended to identify forward-looking statements. Examples of forward-looking statements in this presentation may include, among others, statements regarding: (i) the timing, progress and results of our preclinical and clinical trials; (ii) the evaluation of biomarkers; (iii) the impact of the COVID-19 pandemic on the initiation, progress or expected timing of those trials and the timing of related data, as well as our efforts to adjust trial-related activities to address the impact of the COVID-19 pandemic; (iv) the timing or likelihood of regulatory filings for our product candidates; (v) our manufacturing capabilities and strategy; (vi) the potential benefits and activity of our product candidates; (vii) our expectations regarding the nature of the biological pathways we are studying; (viii) our expectations regarding our FIND-IO platform; and (ix) the potential benefits of our relationships with Dr. Lieping Chen and Yale University.

Various factors could cause actual results to differ materially from those projected in any forward-looking statement. Such risks and uncertainties include, among others: the impact of the ongoing COVID-19 pandemic on our business, including our clinical trials, third parties on which we rely and our operations; our limited operating history and no products approved for commercial sale; our history of significant losses; our need to obtain additional financing; risks related to clinical development, marketing approval and commercialization; and the unproven approach to the discovery and development of product candidates based on our FIND-IO platform. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. For further discussion of these and other factors that could affect the outcome of our forward-looking statements, see our filings with the Securities and Exchange Commission, including in "Risk Factors" and "Special Note Regarding Forward-Looking Statements" in the Risk Factors section and throughout NextCure's Form 10-Q filed with the SEC on November 4, 2021. Except as otherwise indicated, this presentation speaks as of the date indicated herein. Except as required by law, we assume no obligation to update any forward-looking statements, or to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. The information in this presentation is not complete and may be changed.







Advancing Product Development Pipeline

PROGRAMS	TARGET	CELLS	DISCOVERY	PRECLINICAL	PHASE 1	PHASE 2	PHASE 3
PRODUCT CANDIDA	TES						
NC318	S15	Tumors and macrophages	NSCLC, BREAS	it, H&N			
NC318 Anti-PD-1 Combo*	S15	Tumors and macrophages	NSCLC				
NC410	LAIR-2	Myeloid and T cells	NSCLC, H&N, CERVICAL	GASTRIC, CRC,			
NC762	B7-H4	Tumors	NSCLC, BREAS	ST, OVARIAN			
NC525	LAIR-1	Leukemic Stem Cells	AML				
DISCOVERY AND RE	SEARCH PROGRAM	IS					
Multiple Programs	Multiple Targets	Multiple cell types					
*Investigator-initiated	(IIT) trial (Yale Univ	versity)					
		Worldwide	e Rights to	All Program	ns		
							Next©

Agenda

5



Agenda - NC318 Phase 1 & Phase 2

6



NC318 Clinical Trial History and Update

SITC Data

Phase 1

- 3+3 design
- Dose escalation, 8 1600 mg
- 15 tumor types
- 49 patients

Phase 2

7

- Simon 2-stage design
- 400 mg Q2W
- NSCLC, ovarian, H&N and breast
- 47 patients

Amended Phase 2


- S15+ selection (CLIA assay)
- 800 mg Q1W: drug exposure
- NSCLC, H&N and breast

Yale Phase 2 (Combo)


- NSCLC
- Mono therapy: PD-1 refractory
- Pembro combo: PD-1 refractory
- Pembro combo: PD-1 naïve

Next©ure

NC318 Historical Clinical Outcomes







Analysis in All Patients





Disease Total mPFS in Progressive Control Evaluable Disease Responses Disease **Cancer Types** Subjects n=32 (CR+PR+SD) Control (n=54)n=32 (37%) (n=86)² (5.0 months) Lung 1 CR, 1 PR, 13 SD 5.23 15 (45%) 18 33 H&N 1 PR 1(20%)4 5 N/A Breast 1 PR, 3 SD 6 4 (40%) 10 4.8 Ovarian 4 SD 4 (24%) 17 4.04 13 Other¹ 8 SD 8 (38%) 13 21 5.1

¹SD subjects in other types of cancer include Esophageal Cancer (n=1), Endometrial Cancer (n=1), Hepatocellular Carcinoma (n=1), Melanoma (n=3), Merkel cell carcinoma (n=1), and SCC/Basaloid (n=1) ²Total of 96 subjects were treated with 10 subjects determined as non-evaluable (NE) for efficacy based on RECIST v1.1 and or clinical evaluations by principal investigators (PIs)

²Total of 96 subjects were treated with 10 subjects determined as non-evaluable (NE) for efficacy based on RECIST v1.1 and or clinical evaluations by principal investigators (PIs) ³3 SD subjects were censored for PFS analysis


⁴1 SD subject lost to follow up for PFS analysis

N/A: Not Applicable is used where sample size is less than 3 for median analysis. The data extract date is as of 18AUG2021

11




Progression-free Survival in the Absence of S15 Selection



Retrospective Analysis in S15+ Patients




Disease Control Rate Increased in S15+ Patient Population



Soluble S15 Changes Associated with NC318 Dosing

- After infusion, soluble S15 (sS15) increased several fold compared to baseline
- PD was observed with a higher fold increase post-infusion (24 hours)
- PD may also correlate with a higher baseline sS15 level




sS15 May Serve as NC318 Biomarker for Patient Selection & Monitoring

15

Next©ure

NC318 at 800mg Weekly Provides Increased Drug Exposure

PK/PD modeling showed 800mg Q1W would result in ~10-fold increase in drug exposure than achieved with 400mg Q2W




Increased Exposure May Impact Drug Activity and Clinical Outcomes

16


Next©ure


NC318 Phase 1 and Phase 2 Learnings & Current Trials



Agenda – Dr. Roy Herbst

18







Siglec15 as a new target for lung cancer immunotherapy

ARTICLES medicine Siglec-15 as an immune suppressor and potential Lieping Chen, MD PhD target for normalization cancer immunotherapy b a c 10³ P = 0.0015Membrane genes Jurkat-NF-kB/NFAT 12 aAPC CD200 ~6,500 reporter • • B7-1 Number of GFP⁺ objects NS 10 Reporter activity (×10³) CD7 OKT3-• B7-2 8 Roy Herbst, MD PhD Adaptors 10² 6 Mock Transfection Siglec-15 TRAIL 4 BTN3A3 KLRD1 B7-H3 2 GZMB FASL Candidates 10¹ 0 5156 SISATN FASL Reporter 10³ 104 NOCY 10² 10⁵ Ö Scott Gettinger, MD ζ signal Total GFP intensity Membrane d protein Validation with B7-2 B7-H1 B7-DC B7-H2 B7-H3 B7-H4 B7-H5 B7-H6 B7-1 primary T cells Identity (%) 28 22 24 21 28 23 19 20 24 aAPCs in a single well Identity + 43 37 42 45 46 38 37 39 32 similarity (%) David Rimm, MD PhD Jun Wang¹⁵, Jingwei Sun¹⁵, Linda N. Liu², Dallas B. Flies², Xinxin Nie¹, Maria Toki³, Jianping Zhang¹, YaleNewHavenHealth Yalecancer Chang Song², Melissa Zarr², Xu Zhou⁹¹, Xue Han¹, Kristina A. Archer², Thomas O'Neill², Roy S. Herbst⁴, Yale SCHOOL OF MED AgediN.Boto¹³, Miguel F. Sanmamed', Solomon Langermann', David L. Rimm^{® 14} and Lieping Chen^{® 14} 2 **Smilow Cancer Hospital** A Comprehensive Cancer Center by the National Center Institute

WHY DID WE SELECT S15?



Time to & Duration of Disease Control In Lung Cancer



• n = 15

• To date, two subjects with NSCLC (1CR and 1PR) remain on therapy for 2.8 and 2.3 years,

respectively.

YaleNewHavenHealth

Smilow Cancer Hospital


Yalecancer

A Conpre

Yale school of medicine

S15 mAb for use as a companion diagnostic test

- · Tested extra-cellular domain antibodies
- Tested 2 batches (about 6 per batch) of NextCure produced intra-cellular domain mAbs
- Successfully identified IF-7 (below) for use in S15 CLIA validated diagnostic assays



Confirmed Partial Response


74 y/o NSCLC dosed 400 mg every 2 weeks

Prior therapies:

 Immunotherapy: "LAG3/PD-1" (best response stable disease then progression)

BASELINE





Duration of PR: 15+ weeks.

Target lesions -41%

DURATION ON STUDY 24+ Weeks

larget lesions -41%

Target lesions -71%

Diagnostic biopsy:

PD-L1 (TPS)

1-50%

S15

N/A

Week 16

Conclusions

- NC318 has been well tolerated across multiple dose levels
- Adverse event profile consistent with other approved immunotherapies
- NC318 has shown encouraging singleagent anti-tumor activity
 - PD-1 refractory NSCLC: 1 CR, 1 PR, and stable disease in 13 patients (of 32 evaluable patients) with a median PFS of 5.2 months
 - Durable stable disease (>24 weeks observed in multiple tumor types)
- Phase 2 enrollment underway with revised protocol: 800mg Q1W in S15 positive patients


YaleNewHavenHealth Smilow Cancer Hospital



Yale SCHOOL OF MEDICINE

Tolcher et al. SITC 2019 (Yale PI LoRusso) Shum et al SITC 2021

PROJECT 1 – Investigator Initiated SPORE Trial



Agenda - NC410


26






LAIR Biology

LAIR-1 IS IMMUNOSUPPRESSIVE




• Binds collagen and C1q -Collagen density is a barrier to T cell migration and suppresses activation -C1g enhances cancer cell proliferation

LAIR-2 ALLEVIATES IMMUNOSUPPRESSION



• Differs from LAIR-1 - Soluble - Greater affinity for collagen & C1q • Modulates LAIR-1 inhibition

NC410 REMODELS COLLAGEN & NORMALIZES IMMUNE SYSTEM




•NC410, fusion protein of LAIR-2







NC410 Safety & Early Efficacy Data from Cohorts 1-5







Transient Reduction of Soluble C1q: Evidence of NC410 Binding




Transient reduction in C1q is early peripheral pharmacodynamic marker

Implies <u>no safety concern</u> regarding complement activity in circulation

30


NextOure

ECM Remodeling




31

Collagen Derived Products - Early Evidence of Collagen Remodeling




LAIR-2 Levels in Peripheral Blood Increase in a Dose-Dependent Fashion



33


Soluble LAIR-1 in Peripheral Blood Over Time

- Soluble LAIR-1 does not change overtime
- Continue to monitor at higher doses to assess mechanistic role in reducing immunosuppression



34

Early Evidence of Immune Activation in a Patient with Stable Disease




• Demonstrates NC410 enhanced T cell proliferation occurs without increase in LAIR-1 expression

35

NC410 Observations for Cohorts 1-5

CIQ	 Transient reduction is early peripheral pharmacodynamic marker Implies <u>no safety concern</u> regarding complement activity in circulation
CDPs	 Increased C4G, Granzyme B-mediated collagen fragment, suggests activity Reduction in Pro-C3 and Pro-C6, prognosis markers of tumor progression
LAIR-2	 Levels in peripheral blood increase in dose-dependent fashion Suggest mechanistic evidence of immune modulation
SOLUBLE LAIR-1	Does not change overtime
CD4 / CD8	 Time-dependent increase without increase in LAIR-1 expression NC410 enhanced T cell proliferation occurs without increase in LAIR-1 expression
SAFETY & TOLERABILITY	 No DLTs through cohort 5 Analyses ongoing for higher cohorts
36	Next@ure

NC410: Key to Unlock TME and Normalize Immune Response





	CANDIDATE	TARGET	МОА	INDICATION
NC410	LAIR-2 fusion	Collagen & C1q	ECM remodeling & normalizing immune response	Solid tumors
NC525	LAIR-1 mAb	LAIR-1	Blast & LSC killing	Heme-onc

38

Agenda – NC525


39



New Program - NC525 (LAIR-1 mAb)




BIOLOGY



- stem and progenitor cells (HSPCs)
- Current AML treatments do not discriminate between leukemia blast cells and normal blood cells including HSPCs

MOA



Spares HSPCs

UPDATE

- Inhibits colony formation of AML LSCs in vitro
- Inhibits AML growth in MV4-11 derived xenografts (CDX) in vivo
- Restricts AML progression in patient-derived xenografts (PDX) in vivo
- Preclinical data to be presented at ASH
- IND filing Q4 2022



Agenda – Closing Remarks

41



GMP Manufacturing Facility: Added Additional Capacity



Product Development: Getting it Right

NC318 Phase 2	Patient Selection
NC410 Phase 1	Triangulation
NC762 Phase 1	Strategy
NC525 Pre-Clinical	Combos Biomarkers
43	Next©ure

Advancing Product Development Pipeline

TARGET	CELLS	DISCOVERY	PRECLINICAL	PHASE 1	PHASE 2	PHASE 3	NEXT MILESTONE
ATES							
S15	Tumors and macrophages	NSCLC, BREA	st, H&N				Phase 2 update Q4 2022
S15	Tumors and macrophages	NSCLC					Initial Data 1H 2022
LAIR-2	Myeloid and T cells	NSCLC, H&N, CERVICAL	GASTRIC, CRC,				Phase 1 update Q2 2022
B7-H4	Tumors	NSCLC, BREA	ST, OVARIAN				Initial Phase 1 data Q2 2022
LAIR-1	Leukemic Stem Cells	AML					IND filing 2H 2022
ESEARCH PROC	GRAMS						
Multiple Targets	Multiple cell types						IND filing in 2023
itiated (IIT) tria	l (Yale University)						
	Worldw	ide Right	ts to All Pr	ograms			
							Next©u
	S15 S15 LAIR-2 B7-H4 LAIR-1 ESEARCH PROO Multiple Targets	ATES S15 Tumors and macrophages S15 Tumors and macrophages S15 Tumors and macrophages LAIR-2 Myeloid and T cells B7-H4 Tumors LAIR-1 Leukemic Stem Cells ESEARCH PROSE Multiple cell types Multiple Multiple University)	STES S15 Tumors and macrophages NSCLC, BREA S15 Tumors and macrophages NSCLC LAIR-2 Myeloid and T cells NSCLC, H&N, CERVICAL B7-H4 Tumors NSCLC, BREA LAIR-1 Leukemic Stem Cells AML ESEARCH PROGENES Multiple cell types Image: Stem cells Multiple Multiple cell types Image: Stem cells	STES S15 Tumors and macrophages NSCLC, BREAST, H&N S15 Tumors and macrophages NSCLC LAIR-2 Myeloid and T cells NSCLC, H&N, GASTRIC, CRC, CERVICAL B7-H4 Tumors NSCLC, BREAST, OVARIAN LAIR-1 Leukemic Stem Cells AML ESEARCH PROGRAMS Multiple cell types Image: Cells Multiple (IIT) trial (Yale University) Image: Cells Image: Cells	STES S15 Tumors and macrophages NSCLC, BREAST, H&N S15 Tumors and macrophages NSCLC LAIR-2 Myeloid and T cells NSCLC, H&N, GASTRIC, CRC, CERVICAL B7-H4 Tumors NSCLC, BREAST, OVARIAN LAIR-1 Leukemic Stem Cells AML ESEARCH PROGRAMS Multiple cell types Image: Cells Multiple Multiple cell types Image: Cells	STES S15 Tumors and macrophages NSCLC, BREAST, H&N S15 Tumors and macrophages NSCLC LAIR-2 Myeloid and T cells NSCLC, H&N, GASTRIC, CRC, CERVICAL B7-H4 Tumors NSCLC, BREAST, OVARIAN LAIR-1 Leukemic Stem Cells AML ESEARCH PROGRAMS Multiple cell types Image tell	STES S15 Tumors and macrophages NSCLC, BREAST, H&N S15 Tumors and macrophages NSCLC LAIR-2 Myeloid and T cells NSCLC, H&N, GASTRIC, CRC, CERVICAL B7-H4 Tumors NSCLC, BREAST, OVARIAN LAIR-1 Leukemic Stem Cells AML ESEARCH PROGRAMS Multiple cell types Image: Cells Multiple Targets Multiple cell types Image: Cells

Next©ure



Significant Momentum & Milestones in 2022

	NC318	BUILDING PIPELINE	EXPERIENCED	RUNWAY
	On Track	Momentum	Team	2H 2023
45				Next ©ure